![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Safety and Efficacy of Velpatasvir and Sofosbuvir-based Regimens for the Treatment
of HCV Genotype 1-6: Results of the HCV-TARGET Study
|
|
|
Reported by Jules Levin
AASLD Annual Meeting 2017, Washington, DC, USA, October 20-24
Landis, CS; Sulkowski, MS; Reau, N; Lutchman, GA; Vainorius, M; Welzel, T; Zeuzem, S; Khalili, M; Nelson, DR; Lok, AS; Fried, MW; Dong, M; Terrault, N
Limited to treatment duration of 12 weeks for Per Protocol Population (N=306 ).
* Overall Per protocol population (N=333 ) is defined as patients who completed or discontinued prematurely due to lack of efficacy and with available virological outcome.
![1120171](../images/112017/112017-1/1120171.gif)
![1120172](../images/112017/112017-1/1120172.gif)
![1120173](../images/112017/112017-1/1120173.gif)
![1120174](../images/112017/112017-1/1120174.gif)
![1120175](../images/112017/112017-1/1120175.gif)
![1120176](../images/112017/112017-1/1120176.gif)
![1120177](../images/112017/112017-1/1120177.gif)
![1120178](../images/112017/112017-1/1120178.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|